18 reports

  • MELINTA THERAPEUTICS DOMINATED APPROVAL AND M&A NEWS IN THE ANTIBIOTICS SPACE
  • GSK AND DYNAVAX EMERGE AS CLEAR WINNERS, WHILE SANOFI ABSORBS LOSSES IN DENGUE, C. DIFFICILE

Pharmaceutical R& D also saw significant setbacks in 2017.

  • Pharmaceutical
  • Therapy
  • AbbVie Inc.
  • Amgen Inc.
  • Melinta Therapeutics, Inc.
  • Promising Drugs in Clinical Development for MRSA
  • Top Industry Sponsors of MRSA Clinical Trials

Methicillin-Resistant Staphylococcus aureus (MRSA): Competitive Landscape to 2026 Summary Methicillin-resistant Staphylococcus aureus (MRSA) is a widespread Gram-positive bacterium spread through direct contact with infected individuals. It is characterized by multiple drug resistance to beta-lactam...

  • Antibiotic Resistance
  • Pharmaceutical
  • Allergan plc
  • Melinta Therapeutics, Inc.
  • Pfizer Inc.
  • COMPETITORS
  • CONTENTS

COMPANIES, ##% BY LARGE PHARMA COMPANIES AND ##% BY ACADEMIA.

  • Anti-Infective
  • Antibiotic Resistance
  • Pharmaceutical
  • Therapy
  • Melinta Therapeutics, Inc.
  • MELINTA THERAPEUTICS, INC.- COMMUNITY ACQUIRED PNEUMONIA PIPELINE, H1- 2018
  • Untitled

We are one of the key pharmaceutical research organizations with special focus on clinical trials and pipeline products.

  • Infectious Disease
  • Pharmaceutical
  • Therapy
  • Biotest AG
  • Melinta Therapeutics, Inc.
  • 9.4.2 Cempra Pharmaceuticals
  • KEY LATE-STAGE PIPELINE AGENTS FOR MRSA, 2015

PharmaPoint: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Global Drug Forecast and Market Analysis to 2024 Summary With the discovery of penicillin, the first naturally-occurring antibiotic, in 1928, and its mass production in the early 1940s, infections with Staphylococcus aureus were mostly treatable, without...

  • Anti-Infective
  • Antibiotic Resistance
  • Pharmaceutical
  • Therapy
  • Melinta Therapeutics, Inc.
  • 4.4.2 Cempra Pharmaceuticals
  • COMPANIES WITH PROMISING PIPELINE CANDIDATES FOR MRSA IN THE 7MM, 2015

Methicillin-Resistant Staphylococcus aureus (MRSA) - Current and Future Players Summary GlobalData has released its pharma report, “Methicillin-Resistant Staphylococcus aureus (MRSA) - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly...

  • Anti-Infective
  • Antibiotic Resistance
  • Pharmaceutical
  • Therapy
  • Melinta Therapeutics, Inc.
  • MELINTA THERAPEUTICS INC, PHARMACEUTICALS & HEALTHCARE, DEAL DETAILS
  • Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Summary Melinta Therapeutics Inc (Melinta) is a biopharmaceutical company that focuses on the development of novel antibiotics.Its drugs are intended to treat the various bacterial infections. The company’s lead product Baxdela (delafloxacin) has been approved by the US FDA as an IV treatment for serious skin infections...

  • Pharmaceutical
  • Therapy
  • United States
  • Company
  • Melinta Therapeutics, Inc.
  • Rib-X Pharma Withdraws IPO
  • MELINTA THERAPEUTICS INC, PHARMACEUTICALS & HEALTHCARE, DEAL DETAILS

Summary Melinta Therapeutics Inc (Melinta) is a biopharmaceutical company that focuses on the development of novel antibiotics. Its drugs are intended to treat the various bacterial infections. The company’s lead product Baxdela (delafloxacin) has been approved by the US FDA as an IV treatment for serious skin infections...

  • Pharmaceutical
  • Therapy
  • United States
  • Company
  • Melinta Therapeutics, Inc.
  • APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
  • 7.7. ERAVACYCLINE: CURRENT STATUS AND KEY DEVELOPMENTS

INTRODUCTION Since the discovery of penicillin in 1948, antibiotics have emerged as a crucial class of pharmacological interventions responsible for treating several infectious conditions. In addition, antibiotics are also used for prophylactic purposes in patients who have undergone surgery, or immunocompromised patients (cancer...

  • Anti-Infective
  • Antibiotic Resistance
  • Pharmaceutical
  • Therapy
  • Melinta Therapeutics, Inc.
  • KEY LATE-STAGE PIPELINE AGENTS FOR MRSA, 2015
  • OTHER PROMISING PIPELINE PRODUCTS FOR MRSA, 2015

PLOS ONE; ##(##): E##.

  • Anti-Infective
  • Antibiotic Resistance
  • Pharmaceutical
  • Therapy
  • Melinta Therapeutics, Inc.
  • KEY LATE-STAGE PIPELINE AGENTS FOR MRSA, 2015
  • OTHER PROMISING PIPELINE PRODUCTS FOR MRSA, 2015

PLOS ONE; ##(##): E##.

  • Anti-Infective
  • Antibiotic Resistance
  • Pharmaceutical
  • Therapy
  • Melinta Therapeutics, Inc.
  • KEY LATE-STAGE PIPELINE AGENTS FOR MRSA, 2015
  • OTHER PROMISING PIPELINE PRODUCTS FOR MRSA, 2015

PLOS ONE; ##(##): E##.

  • Anti-Infective
  • Antibiotic Resistance
  • Pharmaceutical
  • Therapy
  • Melinta Therapeutics, Inc.
  • TOP DEALS IN (2012 -YTD2016)
  • PARTNERSHIP - DEAL REPORTS

Pharmaceuticals and Healthcare--> Pharmaceuticals-- > Pharmaceutical Manufacturers Pharmaceuticals and Healthcare--> Other--> Veterinary Av.

  • Pharmaceutical
  • Therapy
  • United States
  • Corporate Finance
  • Melinta Therapeutics, Inc.
  • MEIJI SEIKA PHARMA CO LTD
  • ESCHERICHIA COLI INFECTIONS - DORMANT PROJECTS, H1 2018 (CONTD..2), H1 2018

Escherichia coli Infections - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Pipeline Review, H1 2018, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape. Escherichia...

  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Melinta Therapeutics, Inc.
  • Melinta Therapeutics, Inc - Pharmaceutical Pipeline Products Data
  • Melinta Therapeutics, Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

Melinta Therapeutics Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This up-to-the-minute...

  • Pharmaceutical
  • Therapy
  • United States
  • Company
  • Melinta Therapeutics, Inc.
  • Sales Comparisons (Most Recent Fiscal Year)
  • Comparative Business Analysis: Melinta Therapeutics, Inc.

All companies in the industry with more than $## million (U. S. ) in net sales were included.

  • Pharmaceutical
  • Therapy
  • United States
  • Company Financials
  • Melinta Therapeutics, Inc.
  • MEIJI SEIKA PHARMA CO LTD
  • MADAM THERAPEUTICS BV

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2018, provides an overview of the...

  • Antibiotic Resistance
  • Pharmaceutical
  • United States
  • World
  • Melinta Therapeutics, Inc.
  • Other Developmental Activities
  • Other Developmental Activities

Both studies had one-month interim sacrifices and toxicokinetic determinations; the radezolid study also had a one-month recovery arm.

  • Pharmaceutical
  • Therapy
  • United States
  • Company Operations
  • Melinta Therapeutics, Inc.